This company has been acquired
SRRA Stock Overview
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Sierra Oncology, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$54.99 |
52 Week High | US$55.19 |
52 Week Low | US$14.91 |
Beta | 0.015 |
1 Month Change | 0.20% |
3 Month Change | 43.77% |
1 Year Change | 179.42% |
3 Year Change | 143.49% |
5 Year Change | 18.51% |
Change since IPO | -95.54% |
Recent News & Updates
Recent updates
Shareholder Returns
SRRA | US Biotechs | US Market | |
---|---|---|---|
7D | 0.06% | -4.1% | -0.7% |
1Y | 179.4% | 4.0% | 25.9% |
Rentabilidad frente al sector: SRRA exceeded the US Biotechs industry which returned -25.1% over the past year.
Rentabilidad vs. Mercado: SRRA exceeded the US Market which returned -19.1% over the past year.
Price Volatility
SRRA volatility | |
---|---|
SRRA Average Weekly Movement | 11.4% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: SRRA's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: SRRA's weekly volatility (11%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 109 | Stephen Dilly | https://www.sierraoncology.com |
Sierra Oncology, Inc. Fundamentals Summary
SRRA fundamental statistics | |
---|---|
Market cap | US$1.34b |
Earnings (TTM) | -US$102.67m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-13.1x
P/E RatioIs SRRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SRRA income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$59.88m |
Gross Profit | -US$59.88m |
Other Expenses | US$42.79m |
Earnings | -US$102.67m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -4.20 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 1.9% |
How did SRRA perform over the long term?
See historical performance and comparison